65156-94-7 Usage
General Description
5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE is a chemical compound with the molecular formula C9H6ClN3. It is a heterocyclic compound that belongs to the pyrrolopyridine class of chemicals. 5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE is used in pharmaceutical research as a building block for the synthesis of various biologically active molecules, including potential drug candidates. Its structure and reactivity make it a valuable intermediate for the development of new pharmaceuticals and agrochemicals. Its unique properties and potential applications make it an interesting target for further study and development in the field of medicinal chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 65156-94-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,1,5 and 6 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 65156-94:
(7*6)+(6*5)+(5*1)+(4*5)+(3*6)+(2*9)+(1*4)=137
137 % 10 = 7
So 65156-94-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H5ClN2/c8-7-2-1-5-6(10-7)3-4-9-5/h1-4,9H
65156-94-7Relevant articles and documents
PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS
-
Page/Page column 58-59, (2020/12/30)
The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and comp
New bicyclic compounds as crac channel modulators
-
Paragraph 0131; 0146, (2014/06/24)
The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.
NEW CRTH2 ANTAGONISTS
-
, (2013/03/26)
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
